{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:23:51Z","timestamp":1790673831535,"version":"4.1.0"},"reference-count":57,"publisher":"American Society for Clinical Investigation","issue":"19","funder":[{"name":"NIH, LLS","award":["see below"],"award-info":[{"award-number":["see below"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,4]]},"abstract":"<jats:p>The identification of targetable vulnerabilities in the context of therapeutic resistance is a key challenge in cancer treatment. We detected pervasive aberrant splicing as a characteristic feature of chronic lymphocytic leukemia (CLL), irrespective of splicing factor mutation status, which was associated with sensitivity to the spliceosome modulator, E7107. Splicing modulation affected CLL survival pathways, including members of the B cell lymphoma-2 (BCL2) family of proteins, remodeling antiapoptotic dependencies of human and murine CLL cells. E7107 treatment decreased myeloid cell leukemia-1 (MCL1) dependence and increased BCL2 dependence, sensitizing primary human CLL cells and venetoclax-resistant CLL-like cells from an E\u03bc-TCL1\u2013based adoptive transfer murine model to treatment with the BCL2 inhibitor venetoclax. Our data provide preclinical rationale to support the combination of venetoclax with splicing modulators to reprogram apoptotic dependencies in CLL for treating venetoclax-resistant CLL cases.<\/jats:p>","DOI":"10.1172\/jci.insight.121438","type":"journal-article","created":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T11:01:24Z","timestamp":1538564484000},"source":"Crossref","is-referenced-by-count":50,"title":["Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies"],"prefix":"10.1172","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1573-8799","authenticated-orcid":true,"given":"Elisa ten","family":"Hacken","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Valentin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fara Faye D.","family":"Regis","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanye","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian","family":"Werner","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Gruber","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Gill","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Seiler","sequence":"additional","affiliation":[{"name":"H3 Biomedicine Inc., Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Smith","sequence":"additional","affiliation":[{"name":"H3 Biomedicine Inc., Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Thomas","sequence":"additional","affiliation":[{"name":"H3 Biomedicine Inc., Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Buonamici","sequence":"additional","affiliation":[{"name":"H3 Biomedicine Inc., Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela M.","family":"Ghia","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California, San Diego, La Jolla, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Kim","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Z.","family":"Rassenti","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California, San Diego, La Jolla, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan A.","family":"Burger","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Kipps","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California, San Diego, La Jolla, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Meyerson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA."},{"name":"Harvard Medical School, Boston, Massachusetts, USA."},{"name":"Broad Institute, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8698-4957","authenticated-orcid":true,"given":"Pavan","family":"Bachireddy","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA."},{"name":"Harvard Medical School, Boston, Massachusetts, USA."},{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA."},{"name":"Harvard Medical School, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Reed","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2566-3145","authenticated-orcid":true,"given":"Donna","family":"Neuberg","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben D.","family":"Carrasco","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA."},{"name":"Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7898-3073","authenticated-orcid":true,"given":"Angela N.","family":"Brooks","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Engineering, University of California, Santa Cruz, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1993-9013","authenticated-orcid":true,"given":"Anthony","family":"Letai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA."},{"name":"Harvard Medical School, Boston, Massachusetts, USA."},{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA."},{"name":"Harvard Medical School, Boston, Massachusetts, USA."},{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine J.","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA."},{"name":"Harvard Medical School, Boston, Massachusetts, USA."},{"name":"Broad Institute, Cambridge, Massachusetts, USA."},{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2018,10,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-017-0358-1"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nature15395"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nature14666"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1101\/gr.152132.112"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109016"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.09.053"},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10615","article-title":"Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage","volume":"7","author":"Alsafadi","year":"2016","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004105"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.10.005"},{"issue":"7","key":"B11","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/blood.V93.7.2327","article-title":"An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia","volume":"93","author":"Alfarano","year":"1999","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0b013e32835a0142"},{"issue":"1","key":"B13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.leu.2403183","article-title":"Expression and transcriptional regulation of functionally distinct Bmf isoforms in B-chronic lymphocytic leukemia cells","volume":"18","author":"Morales","year":"2004","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.RA117.000539"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1101\/gr.108662.110"},{"issue":"Database issue","key":"B16","first-page":"D377","article-title":"PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees","volume":"41","author":"Mi","year":"2013","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"B17","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1101\/gad.2009411","article-title":"The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region","volume":"25","author":"Folco","year":"2011","journal-title":"Genes Dev"},{"issue":"15","key":"B18","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/bloodadvances.2017007062","article-title":"Novel SF3B1 in-frame deletions result in aberrant RNA splicing in CLL patients","volume":"1","author":"Agrawal","year":"2017","journal-title":"Blood Adv"},{"issue":"17","key":"B19","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1007\/s00018-004-4001-7","article-title":"Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications","volume":"61","author":"Akgul","year":"2004","journal-title":"Cell Mol Life Sci"},{"issue":"20","key":"B20","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1182\/blood-2009-07-233718","article-title":"Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance","volume":"114","author":"Kurtova","year":"2009","journal-title":"Blood"},{"issue":"7","key":"B21","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2006-08-043257","article-title":"Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA","volume":"109","author":"Otake","year":"2007","journal-title":"Blood"},{"issue":"5","key":"B22","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","article-title":"Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members","volume":"9","author":"Certo","year":"2006","journal-title":"Cancer Cell"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.01.042"},{"issue":"2","key":"B24","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/leu.2015.286","article-title":"The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1","volume":"30","author":"Larrayoz","year":"2016","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.32"},{"issue":"10","key":"B26","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1073\/pnas.102181599","article-title":"Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression","volume":"99","author":"Bichi","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"B27","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/0008-5472.CAN-05-3426","article-title":"Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice","volume":"66","author":"Zanesi","year":"2006","journal-title":"Cancer Res"},{"issue":"4","key":"B28","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1182\/blood-2005-12-011213","article-title":"Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia","volume":"108","author":"Johnson","year":"2006","journal-title":"Blood"},{"issue":"16","key":"B29","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1182\/blood-2009-07-233304","article-title":"Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1","volume":"115","author":"Yecies","year":"2010","journal-title":"Blood"},{"issue":"8","key":"B30","first-page":"e302","article-title":"Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors","volume":"100","author":"Thijssen","year":"2015","journal-title":"Haematologica"},{"issue":"25","key":"B31","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1182\/blood-2015-10-675009","article-title":"BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199","volume":"127","author":"Bojarczuk","year":"2016","journal-title":"Blood"},{"issue":"6","key":"B32","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/leu.2014.1","article-title":"Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199","volume":"28","author":"Khaw","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"B33","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1182\/blood-2012-09-457119","article-title":"Targeting the LYN\/HS1 signaling axis in chronic lymphocytic leukemia","volume":"121","author":"ten Hacken","year":"2013","journal-title":"Blood"},{"issue":"7626","key":"B34","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"issue":"2","key":"B35","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"19","key":"B36","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1038\/onc.2015.318","article-title":"Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes","volume":"35","author":"Sveen","year":"2016","journal-title":"Oncogene"},{"key":"B37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.gde.2017.10.010","article-title":"Targeting splicing abnormalities in cancer","volume":"48","author":"Agrawal","year":"2018","journal-title":"Curr Opin Genet Dev"},{"issue":"9","key":"B38","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/nm.4165","article-title":"Therapeutic targeting of splicing in cancer","volume":"22","author":"Lee","year":"2016","journal-title":"Nat Med"},{"issue":"1","key":"B39","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.molmed.2015.11.005","article-title":"Small molecule modulators of pre-mRNA splicing in cancer therapy","volume":"22","author":"Salton","year":"2016","journal-title":"Trends Mol Med"},{"issue":"5","key":"B40","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.celrep.2017.07.025","article-title":"Impact of alternative splicing on the human proteome","volume":"20","author":"Liu","year":"2017","journal-title":"Cell Rep"},{"issue":"6","key":"B41","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/nm.4097","article-title":"Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins","volume":"22","author":"Lee","year":"2016","journal-title":"Nat Med"},{"issue":"3","key":"B42","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ccell.2016.08.006","article-title":"Physiologic expression of Sf3b1(K700E) causes impaired erythropoiesis, aberrant splicing, and sensitivity to therapeutic spliceosome modulation","volume":"30","author":"Obeng","year":"2016","journal-title":"Cancer Cell"},{"issue":"26","key":"B43","doi-asserted-by":"crossref","first-page":"22734","DOI":"10.18632\/oncotarget.4212","article-title":"The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia","volume":"6","author":"Xargay-Torrent","year":"2015","journal-title":"Oncotarget"},{"issue":"10","key":"B44","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1021\/acschembio.6b00399","article-title":"Selectivity in small molecule splicing modulation","volume":"11","author":"Kumar","year":"2016","journal-title":"ACS Chem Biol"},{"issue":"7","key":"B45","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3324\/haematol.2014.122069","article-title":"Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B","volume":"100","author":"Kashyap","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"B46","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-015-0168-9","article-title":"Widespread intron retention diversifies most cancer transcriptomes","volume":"7","author":"Dvinge","year":"2015","journal-title":"Genome Med"},{"issue":"4","key":"B47","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/leu.2017.321","article-title":"Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy","volume":"32","author":"Patel","year":"2018","journal-title":"Leukemia"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1172\/JCI28281"},{"issue":"17","key":"B49","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2012-02-414060","article-title":"Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia","volume":"120","author":"Davids","year":"2012","journal-title":"Blood"},{"issue":"3","key":"B50","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s10637-013-0046-5","article-title":"A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors","volume":"32","author":"Hong","year":"2014","journal-title":"Invest New Drugs"},{"issue":"6","key":"B51","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.4049\/jimmunol.1600915","article-title":"Functional differences between IgM and IgD signaling in chronic lymphocytic leukemia","volume":"197","author":"Ten Hacken","year":"2016","journal-title":"J Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1021\/cb500340w"},{"issue":"6 Pt B","key":"B53","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.jmb.2014.09.030","article-title":"Potent and specific peptide inhibitors of human pro-survival protein Bcl-xL","volume":"427","author":"Dutta","year":"2015","journal-title":"J Mol Biol"},{"key":"B54","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.25541.047","article-title":"Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1","author":"Jenson","year":"2017","journal-title":"Elife"},{"issue":"1","key":"B55","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1091\/mbc.E15-01-0028","article-title":"Mcl-1 involvement in mitochondrial dynamics is associated with apoptotic cell death","volume":"27","author":"Morciano","year":"2016","journal-title":"Mol Biol Cell"},{"issue":"20","key":"B56","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1158\/0008-5472.CAN-15-0457","article-title":"Targeting the miR-221-222\/PUMA\/BAK\/BAX pathway abrogates dexamethasone resistance in multiple myeloma","volume":"75","author":"Zhao","year":"2015","journal-title":"Cancer Res"},{"issue":"25","key":"B57","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/bloodadvances.2017012211","article-title":"Constitutive Ras signaling and Ink4a\/Arf inactivation cooperate during the development of B-ALL in mice","volume":"1","author":"Sewastianik","year":"2017","journal-title":"Blood Adv"}],"container-title":["JCI Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/insight.jci.org\/articles\/view\/121438\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:41:11Z","timestamp":1779194471000},"score":1,"resource":{"primary":{"URL":"https:\/\/insight.jci.org\/articles\/view\/121438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,4]]},"references-count":57,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2018,10,4]]},"published-print":{"date-parts":[[2018,10,4]]}},"alternative-id":["10.1172\/jci.insight.121438"],"URL":"https:\/\/doi.org\/10.1172\/jci.insight.121438","relation":{},"ISSN":["2379-3708"],"issn-type":[{"value":"2379-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,4]]},"article-number":"e121438"}}